IGF1 and muscular disease: Knowing that IGF-1 could be a possible therapeutic target for the treatment of muscle atrophy in muscular diseases related to the nervous system [31], we aimed to better understand the time-dependent changes in the IGF-1 system after denervation, including the analysis of IGFBP-5 and its regulators, PAPP and STC.